Clinical Trial Update: A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia [Phase 3]

View source ↗

Summary

This update describes a completed Phase 3 study evaluating the safety, tolerability, and treatment response of paliperidone palmitate in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED